Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.49 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260235 | 1.00 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8257128 | 1.00 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL13387564 | 0.93 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL4719490 | 0.93 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL16526220 | 0.88 | GAA (0.66) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL2575225 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL4282209 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL4282204 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL28019672 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL1827279 | 0.86 | EPHX1 (0.64) | GAAMAPK1HTTSMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | GAA 204/4885MAPK1 3743/4885HTT 4113/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | GAA 217/4885MAPK1 2555/4885HTT 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.